Molecular Chemotherapies in Gynecologic

Kathryn Kennedy and William Robinson

Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA

*Corresponding author: Kathryn Kennedy, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA, USA, Tel: 9784001881; Fax: 312 695 0370; E-mail: kkennedy@tulane.edu

Received date: August 31, 2017; Accepted date: September 12, 2017; Published date: September 18, 2017

Abstract

The development of chemotherapy agents that precisely target specific molecular structures in cancer cells has become a priority in oncology research. In principal, this method halts cancer cell proliferation while allowing normal function of healthy cells. These molecular-based chemotherapy agents target many types of molecules involved in the growth, spread, and survival of malignant cells. Several of these target molecules have been identified in female genital tract malignancies, and multiple agents targeted at those molecules have been developed as treatment.

This review outlines three major types of targeted agents that have clinical relevance in the treatment of gynecologic cancers. The first group of drugs inhibits vascular endothelial growth factor (VEGF), which normally facilitates angiogenesis. The second group inhibits poly ADP ribose polymerase, a base-excision enzyme that repairs single-strand DNA breaks. The final category is a set of drugs that inhibit programmed cell death protein 1, an immune checkpoint that normally prevents autoimmunity. Therapeutic benefit has been demonstrated for each of these drug types in gynecologic, and particularly ovarian, cancers.

New agents and applications for these agents have been developing at a rapid pace in each of these categories. FDA approval has been accelerated for several of these agents in recent years, suggesting a significant change in the process by which new drugs enter the clinical armamentarium. In short, the development of molecularly-targeted drugs for the treatment of cancer is a promising and rapidly-moving field.

Keywords: Angiogenesis; Female genital tract malignancies; Signal transduction; Gene expression; Apoptosis inhibition; Angiogenesis inhibition; Immunomodulation

Introduction

Historically, chemotherapy for cancer have been based on the use of cytotoxic agents that kill rapidly-dividing cells, typically including at least some non-malignant cells. The advent of agents targeted at specific molecules associated with cancer has been revolutionary, and have generally demonstrated much less toxicity than traditional chemotherapy, with varying (but often significant) degrees of effectiveness [1,2]. Targets include molecules for signal transduction, gene expression, apoptosis inhibition, angiogenesis inhibition, and immunomodulation. Since cancer cells rely on these molecules for proliferation and survival, targets that precisely inhibit those molecules could stop malignant progression.

These principles also apply to gynecologic malignancies, and there is a great need for novel therapeutic agents in these cancers. This is especially true for ovarian cancer. Nearly 80% of women diagnosed with epithelial ovarian cancer, for example, will achieve a complete response to traditional cytotoxic chemotherapy (generally a combination of cis- or carboplatin and a taxane). However, in the majority of cases, these responses are not durable, and as many as 75% will eventually succumb to the disease, demonstrating the urgent need for new treatments. Thus far, three molecular targets have demonstrated efficacy in gynecologic malignancies. Vascular endothelial growth factor (VEGF), which normally facilitates angiogenesis, is the target of bevacizumab, an agent that is FDA-approved for cervical, ovarian, fallopian tube, and primary peritoneal malignancy. Poly ADP ribose polymerase (PARP), which normally repairs single-strand DNA breaks, is the target for niraparib, olaparib, and rucaparib, which are FDA-approved for ovarian, fallopian tube, and primary peritoneal cancer [3]. Finally, PD-1, the cell surface protein which is responsible for programmed cell death, has been targeted by pembrolizumab, and has been FDA-approved for the treatment of multiple solid malignancies, including ovarian and cervical cancer. Avelumab is another anti-PD-1 agent for which two phase III clinical trials are currently in progress. The discussion that follows reviews each of these of molecular chemotherapies and their roles in gynecologic cancer.

Discussion

The first category of molecular chemotherapies is VEGF inhibitors, of which bevacizumab is the predominant drug and first of its kind to become commercially available in the United States. Cancer cells rely on VEGF to stimulate angiogenesis through endothelial cell stimulation in settings of oxygen deprivation. Bevacizumab is a recombinant humanized monoclonal antibody that binds VEGF in the bloodstream, therefore preventing it from binding to its cell surface receptor and stimulating angiogenesis [4]. In 2014, bevacizumab was approved by the FDA for intravenous (IV) infusion in combination with paclitaxel, liposomal doxorubicin, or topotecan for the treatment of platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer. This was based on the AURELIA study, an international, two-arm trial in which subjects were randomized to receive one of the above-mentioned drugs with or without
bevacizumab. This trial showed a statistically significant progression-free survival (PFS) of 6.8 months for the subjects who received bevacizumab, compared with 3.4 months for those who did not [5]. Bevacizumab was also approved for platinum-sensitive epithelial ovarian, fallopian tube, and primary peritoneal cancers based on the GOG 213 and OCEANS studies. In Gynecologic Oncology Group (GOG) study #213, bevacizumab plus chemotherapy (carboplatin and paclitaxel) demonstrated an increase in median overall survival compared with chemotherapy alone (42.6 vs. 37.3 months). In the OCEANS study, bevacizumab plus chemotherapy (carboplatin and gemcitabine) resulted in significant improvement in PFS compared with chemotherapy alone (12.4 vs. 8.4 months) [6]. Also in 2014, bevacizumab was approved for the treatment of persistent, recurrent, or metastatic cervical cancer in combination with paclitaxel, cisplatin, or topotecan, based on GOG 240, which compared PFS of bevacizumab with chemotherapy to chemotherapy alone. This study demonstrated a statistically significant PFS (16.8 vs. 12.9 months) in the group receiving bevacizumab [7]. Since then, bevacizumab has become a mainstay of both ovarian and cervical cancer treatment. A second VEGF-inhibitor, cediranib, has also shown promise; results from a phase II clinical trial show that the combination of cediranib with the PARP inhibitor olaparib is significantly more effective against recurrent platinum-sensitive ovarian cancer than olaparib alone (PFS of 17.7 vs. 9 months) [8]. VEGF inhibitors are not without side effects, however, including hypertension, fatigue, bleeding (particularly nosebleeds), headache, rash, and bowel perforation and fistula formation in up to 3% of patients [9].

The second major category of molecular chemotherapy agents for gynecologic cancers is the PARP inhibitors. PARPs are enzymes that perform base excisions in damaged DNA, thus repairing single-strand breaks. Inhibiting PARP allows these breaks to accumulate, which in turn leads to double-stranded breaks when the DNA replicates [10]. In normal cells, these breaks can still be repaired by homologous recombination. Tumor suppressor proteins BRCA1 and 2 play a substantial role in this process, and thus cancer cells with defective BRCA1 and 2 are unable to perform this repair [11]. The accumulation of double-stranded breaks then leads to cell death [12,13]. A second mechanism by which PARP inhibitors work has also been described and has been termed a 'poisoning' mechanism. When the PARP inhibitor and PARP are bound, PARP is unable to dissociate from DNA. The inhibitor-PARP-DNA complexes then accumulate, which causes cytotoxicity. For this reason, the use of PARP inhibitors is not reliant on the first, catalytic mechanism or limited to BRCA1 and 2-mutated cancers [14]. Three oral PARP inhibitors have been approved by the FDA for use in ovarian cancer: olaparib in December 2014, rucaparib in December 2016, and niraparib in March 2017. Each of these agents varies in their efficacy as a catalytic PARP inhibitor and as a PARP ‘poison’, as shown in Table 1. Each agent’s ability to inhibit the catalytic activity of PARP is independent of its potency as a PARP ‘poison’. Olaparib, for example, has been consistently shown to be a potent catalytic PARP inhibitor, but is not as potent a cytotoxic agent as niraparib. For this reason they have different clinical indications, as shown in Table 1. Also shown in Table 1 are the studies upon which FDA approval was based. Of note, the more recent agents have received special designations for accelerated approval, and are no longer necessarily subject to the typical FDA requirement of having completed two Phase III clinical trials [15]. Side effects of these agents include nausea, vomiting, fatigue, anemia, thrombocytopenia, myelodysplastic syndrome, and acute myeloid leukemia. Several additional PARP inhibitors are increasingly clinically relevant, such as veliparib (ABT-888), which was associated with a median PFS of 8.18 months in a Phase II trial examining treatment of BRCA1/2 mutated ovarian, fallopian tube, and primary peritoneal cancers. Phase III trials are currently in progress [16].

<table>
<thead>
<tr>
<th>Niraparib (MK-4827)</th>
<th>Olaparib</th>
<th>rucaparib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potency to inhibit catalytic PARP activity</td>
<td>Weak</td>
<td>Strong</td>
</tr>
<tr>
<td>Potency as a cytotoxic PARP poison</td>
<td>Strong</td>
<td>Intermediate</td>
</tr>
<tr>
<td>FDA Approved For:</td>
<td>Maintenance therapy for platinum-sensitive recurrent high-grade serous epithelial ovarian, fallopian tube, primary peritoneal cancer with or without BRCA mutations (March 2017)</td>
<td>Monotherapy for germline BRCA-mutated ovarian cancer that has failed 3 or more previous lines of chemotherapy (December 2014)</td>
</tr>
<tr>
<td>Trials upon which the FDA based approval</td>
<td>NOVA Trial (Phase III): PFS in the gBRCA mut cohort was significantly increased with niraparib (21.0 vs. 5.5 months) and PFS in the non-gBRCAmut cohort was also increased (9.3 vs. 3.9 mo) [17]</td>
<td>Monotherapy: Kaufman, et al. (Phase II) Maintenance: SOLO-2 (Phase III) showed PFS 19.1 vs. 5.5 mo [18] Study 19 (Phase III) showed PFS of 8.4 vs. 4.8 mo [19]</td>
</tr>
<tr>
<td>Special FDA Designations</td>
<td>Fast Track, Priority Review, Breakthrough Therapy, Orphan Drug</td>
<td>Accelerated Approval for monotherapy Priority Review for maintenance therapy</td>
</tr>
</tbody>
</table>

Table 1: Catalytic PARP inhibitor and as a PARP ‘poison.'
The final class of molecular chemotherapy agents discussed in this review is the PD1 inhibitor group. PD-1 is a cell surface receptor expressed on T cells. Normally, PD-1 binds to ligands PD-L1 and PD-L2, which reduces T cell proliferation, T cell signaling, cytokine production, and increases T cell susceptibility to apoptosis. This prevents pathologic immune response in healthy patients and thus prevents autoimmunity. When malignant cells express these ligands, however, they are allowed to proliferate uninhibited by these T-cell mechanisms. PD-1 inhibitors shut down this checkpoint by preventing the binding of PD-1 to its ligands, thus allowing effector T cells to mount an immune response against the tumor [22]. The FDA has recently approved Pembrolizumab for use in multiple solid tumors, including gynecologic cancers, which express this marker. Plus, several agents of this type are currently being evaluated in phase III clinical trials. Because initial studies showed that ovarian cancers with high expression of PD-L1 were associated with poorer outcomes, PD1 inhibitors have been selected as a potential molecular target for ovarian cancer treatment [23]. Nivolumab and Pembrolizumab are anti-PD1 IgG4 monoclonal antibodies that have shown 15% and 11.5% objective response rates (ORR) in phase II and phase Ib studies of ovarian cancer patients, respectively [24,25]. Avelumab is an anti-PD-L1 IgG1 monoclonal antibody that showed an ORR of 9.7% in patients with refractory or recurrent ovarian cancer in a phase Ib study [26]. This has led to two phase III studies; the first is avelumab for front-line therapy in ovarian cancer in combination with carboplatin and paclitaxel (Javelin ovarian 100), and the second is avelumab for recurrent platinum-resistant disease (Javelin ovarian 200) [27]. Other anti-PD-L1 agents in earlier stages of development for ovarian cancer treatment include the IgG1 monoclonal antibodies durvalumab and atezolizumab [28]. While side effects for this genre of drugs are common (about 40% of patients) they are generally not severe (only 5% using Common Terminology Criteria for Adverse Events), and include rash, pruritis, diarrhea, arthralgia, arthritis, myalgia, myositis, thyroiditis, hypothyroidism, hypophysitis, and infusion-related reactions [29,30].

Conclusion

As the above discussion shows there are numerous promising possibilities for molecular chemotherapies in the treatment of gynecologic malignancies, and particularly in ovarian cancer. VEGF inhibitors, PARP inhibitors, and PD1 inhibitors are the leading molecular chemotherapy agents of this type. The development of these agents has made rapid progress in the past decade, in part due to the accelerated-approval designations the FDA has assigned to many of them. Rucaparib, for instance, received Breakthrough Therapy, Priority Review, and Orphan Drug designations, and was approved without completion of any phase III trials. New applications for existing drugs are also in rapid development, such as the combination of olaparib with radiotherapy, which has already shown that low doses of olaparib cause radio sensitization and therefore may be a new and valuable type of treatment for ovarian cancer [31].

The FDA has not taken acceleration of the approval process for these agents lightly. Unexpected outcomes or toxicities have occurred in the wake of expedited approvals. However, the high mortality of ovarian cancer, plus the fact that phase III trials often require years to complete, suggest that changes in the approval process would be very well-received by those affected by this disease. Furthermore, the fast pace at which new drugs are being developed means that by the time phase III trials are completed, newer, possibly superior, drugs may exist. The use of surrogate molecular markers as endpoints in the place of traditional measures of progression-free and overall survival is being carefully evaluated. Patient-reported outcomes are also becoming much more important to the process of drug development and approval. If drug development continues at this rate, an overall restructuring of the drug approval process may become necessary and reasonable. In conclusion, the development of molecular-based chemotherapies for gynecologic cancers is a rapidly progressing field, and many of these drugs have proven thus far to be very promising in the treatment of these devastating illnesses.


